To Get more Insights,  Request A Free Sample 

Unlocking New Frontiers in Cellular Research and Personalized Medicine

• The Rise of Organ-on-a-Chip and Microphysiological Systems: A transformative opportunity lies in using primary cells to create complex, multi-organ systems on microfluidic chips. In 2024, the number of commercially available organ-chip models exceeded 150 distinct types, a significant increase. Major pharmaceutical companies have initiated over 50 new drug development programs using these systems to get more predictive human data. By 2025, regulatory bodies are expected to accept data from over 20 qualified organ-chip platforms for IND submissions, opening a massive market for specialized primary cells optimized for these advanced devices.
• AI-Powered Cell Analytics and High-Throughput Phenotyping: The integration of artificial intelligence with cell imaging is unlocking new value for the primary cells market  growth. In 2025, over 100 petabytes of imaging data from primary cell assays will be analyzed by AI algorithms to identify novel drug targets and toxicity signatures. Companies are investing heavily, with over US$ 500 million in venture funding directed toward AI-driven cell analysis startups in 2024. This creates a demand for highly consistent and well-characterized primary cells to feed these data-hungry platforms, enabling a new era of predictive, high-throughput biology.

Two Pillars Defining Primary Cells Market Demand

Cell and Gene Therapies Propel Unprecedented Demand for Human Cells

The exponential growth of the cell and gene therapy pipeline is a primary demand driver for the market. In 2024, the number of patients enrolled in CAR-T therapy clinical trials globally surpassed 15,000. This clinical activity is supported by significant investment, with over US$ 18 billion in venture capital flowing into cell therapy companies in 2024. Regulatory support remains strong; the FDA granted more than 80 regenerative medicine advanced therapy (RMAT) designations in the same year, expediting development. The number of approved cell therapies on the market reached 35 globally by the end of 2024.

Manufacturing across the global primary cells market is scaling rapidly to meet the need for these living medicines. Global capacity for viral vector production, essential for many gene-modified cell therapies, exceeded 500,000 liters in 2024. The number of specialized contract development and manufacturing organizations (CDMOs) offering cell therapy services grew to over 150 worldwide. The average therapeutic dose of a cell therapy product in 2025 requires starting material from over 1 billion primary cells. Investment in new biomanufacturing facilities exceeded US$ 9 billion in 2024. The number of commercial doses of cell therapies administered surpassed 25,000 in 2024. The total number of ongoing clinical trials for all cell therapies is projected to reach 1,800 by the end of 2025.

Drug Discovery and Toxicology Testing Rely Heavily on Primary Cell Models

The second pillar supporting the primary cells market is its indispensable role in modern drug discovery and safety testing. The drive to reduce animal testing saw the number of in vivo toxicology studies decrease by 1.2 million globally in 2024, with primary cell assays filling the gap. The market for 3D cell culture products was valued at US$ 1.9 billion in 2024, with primary cells being the key component. Over 400 new organoid models for rare diseases were developed and commercialized in 2024. The use of high-content screening systems to analyze primary cells increased the number of data points per experiment to over 10,000.

Investment in these predictive models is robust. Pharmaceutical companies allocated over US$ 4.5 billion to acquire advanced in-vitro models in 2024. The number of compounds that failed late-stage clinical trials due to unforeseen toxicity was reduced by an estimated 200 in 2024, attributed to better preclinical screening with primary cells market. In 2025, the number of automated liquid handling workstations for cell-based assays is expected to exceed 75,000 units globally. The market for primary hepatocytes used in toxicology testing was valued at US$ 250 million in 2024. Over 5,000 research labs globally adopted primary cell-based cardiotoxicity assays in 2024. The number of peer-reviewed publications on primary cell toxicology models surpassed 12,000 in 2024.

Segmental Analysis

Hematopoietic Cells Spearheading Growth in the Primary Cells Market

Hematopoietic primary cells are poised to be the fastest-growing segment, a trend fueled by their critical role in pioneering medical research and therapies. Their importance in regenerative medicine and treatments for blood cancers is a primary driver of their rapid expansion. Globally, over 1.3 million new cases of hematological malignancies were reported in 2019, creating a vast and urgent need for relevant cellular models for research. The rising incidence of these cancers directly contributes to the escalating demand for hematopoietic cells in both research and clinical settings, such as the more than 84,000 hematopoietic stem cell transplants (HCT) performed annually worldwide.

The therapeutic use of HCT continues to be a significant factor in the segment's growth. Furthermore, extensive research into stem cell biology, where hematopoietic stem cells are a cornerstone, opens up new avenues for their application. In the United States alone, 23,152 HCTs were performed in 2023, illustrating the high volume of clinical procedures that depend on these cells. As the scientific community delves deeper into treating complex diseases, the versatility and therapeutic potential of hematopoietic cells will ensure their sustained and robust growth within the dynamic Primary cells market.

• Leukemia is the second leading cause of cancer death among children and adolescents.
• Projections estimate that new global cases of hematological malignancies will reach approximately 4.6 million by 2030.
• The number of HCTs for acute myeloid leukemia increased by nearly 55% between 2009 and 2016.

ADME Toxicology Testing Driving Significant Primary Cell Demand

ADME (Absorption, Distribution, Metabolism, and Excretion) toxicology testing commands a substantial 62% of the primary cells market, a dominance rooted in the need for more predictive preclinical testing models. Primary cells, particularly human hepatocytes, are the gold standard for in vitro drug metabolism and toxicity screening. Their ability to predict human responses helps address the high failure rate in drug development, where unmanageable toxicity accounts for approximately 30% of clinical trial failures. A key advantage is identifying toxicity issues early, potentially saving a fraction of the over $1 billion average cost to develop a single successful drug.

The strong demand is also a response to regulatory shifts away from animal testing, such as the FDA Modernization Act 2.0 signed into law in 2022. This legislation no longer mandates animal testing and explicitly allows for alternatives, propelling the adoption of cell-based assays. Researchers use primary cells from various organs to create comprehensive safety profiles for drug candidates. As the pharmaceutical industry strives for greater efficiency, the role of primary cells in ADME toxicology will continue to expand, solidifying its position as a cornerstone of the Primary cells market.

• Cardiovascular, hepatic, and central nervous system toxicities account for 70% of toxicity-related drug failures.
• The FDA received a dedicated $5 million in the federal budget to support the development of non-animal testing methods.
• Poor drug-like properties, often assessed in ADME studies, contribute to 10-15% of clinical trial failures.

Pharmaceutical and Biotech Firms Powering the Primary Cells Market

Pharmaceutical and biotechnology companies are the largest and fastest-growing end-users, a trend propelled by their intensive research and development activities. These companies are the primary consumers of primary cells, utilizing them in every stage of drug discovery. The immense scale of this R&D is reflected in the nearly $288 billion spent by the global pharmaceutical industry in 2024 alone. The increasing global investment in developing biologics, cell therapies, and personalized medicine is a major impetus for the high demand for primary cells within these organizations.

The strategic shift to more physiologically relevant systems is critical for improving the translatability of preclinical findings. This is vital in the primary cells market  given that the U.S. FDA approved 55 new drugs in 2023, each having undergone extensive preclinical evaluation often involving primary cells. By integrating primary cell-based assays, these firms can make more informed decisions, enhancing the success rate of their R&D pipelines. The continuous expansion of these industries, coupled with their substantial R&D budgets, will ensure their continued leadership and growth in the Primary cells market.

• The FDA's Center for Biologics Evaluation and Research (CBER) approved a record 17 new agents in 2023.
• In 2024, the top 20 pharmaceutical companies collectively spent approximately $180 billion on R&D.
• Of the 55 drugs approved by the FDA in 2023, 17 were biologics.

Human-Sourced Cells Unwavering Dominance in the Primary Cells Market

With a commanding 71% share, human-derived cells are the undisputed frontrunners in the primary cells market. The immense demand is driven by their superior biological relevance, offering researchers a model that closely mimics human physiology. A critical factor for their dominance is the ability to generate more accurate data for drug discovery, reducing reliance on animal models. The pursuit of personalized medicine further solidifies this position, as demonstrated by the more than 4,099 cell and gene therapies currently in development, all of which rely on human cells. This surge in advanced therapy candidates underscores the indispensable role of human primary cells in creating patient-specific treatments and advancing our understanding of disease.

The continued growth is supported by substantial investments in biomedical research, with the pipeline of cell and gene therapies signaling a robust future. For instance, as of early 2024, there were over 4,000 such therapies in various stages of development, a number that highlights the massive scale of research activities requiring high-quality human cells. The increasing focus on innovative treatments for both common and rare diseases propels the demand in the ever-evolving Primary cells market, ensuring human-sourced cells remain the cornerstone of modern biomedical research and therapeutic development.

• In 2024, biopharma funding reached a 10-year high of $102 billion, excluding the pandemic peak years.
• There are currently over 2,500 active Investigational New Drug (IND) applications for cell and gene therapies.
• Government and private investment in precision medicine continues to expand globally.

 To Understand More About this Research:  Request A Free Sample 

 Regional Analysis 

North America Commands Global Cellular Research and Commercialization Engine

North America leads the global primary cells market with over 52% market share, a position built on an unparalleled ecosystem of funding, innovation, and commercial activity. The U.S. National Institutes of Health (NIH) propelled foundational research with over $450 million in grants for cell and gene therapy projects in 2024. This translates into a robust clinical pipeline, with the FDA managing over 1,200 active Investigational New Drug (IND) applications for cell therapies in early 2025. The regulatory path to market is well-defined, with the FDA's Center for Biologics Evaluation and Research (CBER) approving 5 new cell therapy Biologics License Applications (BLAs) in 2024. Over 18,000 patients in the U.S. received treatment with commercially approved CAR-T therapies in the same year.

The region's dominance in the global primary cells market  is further solidified by a vibrant investment landscape and expanding infrastructure. In the first quarter of 2025, private equity and venture capital firms invested over $8 billion into U.S.-based biotech companies. Innovation hubs are thriving; the Boston/Cambridge area alone saw the launch of over 25 new biotech startups focused on cell-based technologies in 2024. To meet clinical and commercial demand, 12 new large-scale cell therapy manufacturing facilities broke ground in the United States in 2024. Canada contributes significantly, with its Stem Cell Network awarding 34 new research grants in its 2024 competition. California’s Institute for Regenerative Medicine (CIRM) also committed funding to 42 new projects in its latest round, cementing the region's leadership.

Europe Drives Collaborative Innovation and Advanced Regulatory Frameworks

Europe’s strength in the primary cells market is defined by its collaborative research networks and sophisticated regulatory environment. The European Medicines Agency (EMA) granted 18 advanced therapies PRIME (PRIority MEdicines) designations in 2024, expediting the development of promising treatments. The continent hosts a vast clinical landscape, with over 450 new clinical trials for Advanced Therapy Medicinal Products (ATMPs) initiated across member states in 2024. Funding is robust, with the Horizon Europe program’s Health Cluster allocating over €1.5 billion to new projects. The UK’s Cell and Gene Therapy Catapult network expanded to include over 300 collaborating companies and institutions.

National initiatives provide further momentum. Germany's Federal Ministry of Education and Research (BMBF) launched a new €100 million funding initiative for translational cell research in 2024. In France, the national biotherapy accelerator program onboarded 15 new companies. The UK Biobank, a critical resource, dispatched over 400,000 biological samples to researchers worldwide. Infrastructure is also growing, with 8 new GMP-certified manufacturing suites for cell therapies opening in the UK in 2024. Across Europe, the number of patients treated at JACIE-accredited transplant centers surpassed 45,000, showcasing a deep capacity for delivering complex cellular procedures.

Asia Pacific Accelerates as a Hub for Manufacturing and Clinical Scale-Up

The Asia Pacific region is rapidly ascending as a critical hub for clinical development and large-scale manufacturing in the primary cells market. China is at the forefront of clinical research, with its National Medical Products Administration (NMPA) accepting over 350 new applications for cell therapy clinical trials in 2024. The country's research output is massive, with Chinese institutions filing over 5,000 new patents related to cell-based technologies. Japan continues its pioneering role in regenerative medicine, with the Agency for Medical Research and Development (AMED) funding 85 new projects in 2024.

Investment and infrastructure are expanding across the regional primary cells market . Singapore’s Biopolis science park saw the commissioning of 4 new dedicated bioprocessing facilities in 2024. South Korea’s Ministry of Food and Drug Safety granted conditional approval to 3 new cell therapy products. Australia's Medical Research Future Fund (MRFF) awarded over AUD 120 million in grants for stem cell and genomics research. CSL Behring also committed AUD 250 million to expand its R&D and manufacturing hub in Melbourne. In India, the Indian Council of Medical Research (ICMR) funded the establishment of 10 new Centers for Advanced Research in cell biology, signaling the region’s broad commitment to growth.

Top 10 Strategic Investments and Acquisitions In Primary Cells Market

1. Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion
   In a major move to bolster its liver disease portfolio, Gilead completed its acquisition in March 2024, gaining access to novel investigational therapies that rely on primary cell models for validation.
2. Novo Holdings to Acquire Catalent for $16.5 Billion
   Announced in February 2024, this mega-deal will see the parent of Novo Nordisk acquire the leading CDMO, securing critical manufacturing capacity for cell and gene therapies.
3. GSK Completes Acquisition of Aiolos Bio for $1.4 Billion
   In February 2024, GSK acquired the clinical-stage biopharmaceutical company, strengthening its respiratory pipeline with therapies developed using advanced primary cell assays.
4. Astellas Acquires Propella Therapeutics for Approximately $175 Million
   Finalized in February 2024, this acquisition brings in a pipeline of cancer therapies, including a prostate cancer treatment platform heavily reliant on primary cell line development.
5. Danaher Completes $5.7 Billion Acquisition of Abcam
   In December 2023 but closed in 2024, this acquisition combines Danaher’s life science portfolio with Abcam’s essential antibodies and reagents used extensively in primary cell research.
6. ElevateBio Secures $401 Million in Series D Funding
   In May 2023 with tranches extending into 2024, this massive funding round is aimed at advancing the company's technology-driven platforms for cell and gene therapy development, giving a boost to the primary cells market  growth.
7. Capstan Therapeutics Launches with $165 Million in Financing
   Announced in February 2024, this financing supports the development of in vivo CAR-T therapies, a next-generation approach that is modeled and tested using primary immune cells.
8. Bayer Closes Acquisition of Asklepios BioPharmaceutical (AskBio)
   With final payments made in early 2024, Bayer solidified its multi-billion dollar acquisition to build a leading position in the AAV-based gene therapy space.
9. Century Therapeutics Announces $60 Million Private Placement
   In March 2024, the developer of iPSC-derived cell therapies secured new funding to advance its pipeline of next-generation cancer treatments into clinical trials.
10. Novo Nordisk to Acquire Cardior Pharmaceuticals for up to €1.025 Billion
    In March 2024, Novo Nordisk agreed to acquire the German biotech, targeting cardiac disease with therapies developed through deep research into primary cardiac cell RNA.

Top Companies in the Primary Cells Market

• AllCells
• Creative Bioarray
• Cureline
• American Type Culture Collection
• Axol Biosciences Ltd.
• Lonza Group, AG
• Cell Biologics, Inc.
• Thermo Fisher Scientific
• Merck KGaA
• PromoCell
• STEMCELL Technologies
• ZenBio
• Other Prominent Players

Market Segmentation Overview

By Source

• Animal Source
• Human Source

By Type

• Hematopoietic
• Hepatocytes
• Renal Cells
• Gastrointestinal Cells
• Skin Cells
• Lung Cells
• Other Types

By End Users

• Pharmaceutical & Biotechnology Companies
• Research Institutes

By Application

• ADME Toxicology Testing
• Other Applications

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa (MEA)
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America